Regulation of cardiac hypertrophy by RNA readers
- Center for Translational and Experimental Cardiology (CTEC), Department of Cardiology, University Hospital Zurich and University of Zürich, Schlieren 8952, Switzerland
- University Heart Center, Cardiology, University Hospital Zurich, Zurich 8091, Switzerland
- Corresponding author: francesco.paneni{at}uzh.ch
This extract was created in the absence of an abstract.
A deep understanding of the mechanisms regulating cardiac response to stress is of paramount importance to develop new mechanism-based therapeutic approaches tackling pathological cardiac remodeling in heart failure (Martin et al. 2023). Available therapies exert a significant, yet modest effect on cardiac hypertrophy regression in patients with heart failure with reduced (HFrEF) and preserved ejection fraction (HFpEF) (Martin et al. 2023). This helps to explain the unacceptably high residual risk in heart failure patients despite the availability of effective drugs such as renin-angiotensin-system (RAS) blockers, SGLT2 inhibitors, and GLP1-receptor agonists (Fatima et al. 2023).
Although our genetic makeup is certainly linked to pathological cardiac remodeling (Morita et al. 2008), most of the observed phenotypic variation is driven by nongenetic factors (Costantino et al. 2018). Exposure to environmental stimuli has been shown to derail gene expression during the course of life mainly via chemical modifications of DNA/histone complexes and RNA …
